Interobserver Agreement Rates on Fibroblast Activation Protein Inhibitor-Directed Molecular Imaging and Therapy

被引:8
|
作者
Serfling, Sebastian E. [1 ]
Hartrampf, Philipp E. [1 ]
Zhi, Yingjun [2 ]
Higuchi, Takahiro [1 ,3 ]
Rowe, Steven P. [4 ]
Bundschuh, Lena [5 ]
Essler, Markus [5 ]
Buck, Andreas K. [1 ]
Bundschuh, Ralph Alexander [5 ]
Werner, Rudolf A. [1 ,4 ]
机构
[1] Julius Maximilian Univ Wurzburg, Dept Nucl Med, Univ Hosp Wurzburg, Wurzburg, Germany
[2] Julius Maximilian Univ Wurzburg, Dept Otorhinolaryngol Aesthet & Reconstruct Head, Wurzburg, Germany
[3] Okayama Univ, Fac Med Dent & Pharmaceut Sci, Okayama, Japan
[4] Johns Hopkins Sch Med, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD USA
[5] Univ Hosp Bonn, Dept Nucl Med, Venusberg Campus 1, D-53127 Bonn, Germany
基金
日本学术振兴会;
关键词
fibroblast activation protein inhibitor; FAPI; molecular imaging; theranostics; endoradiotherapy; RADS; CANCER; CLASSIFICATION;
D O I
10.1097/RLU.0000000000004189
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objectives Fibroblast activation protein (FAP) has emerged as a novel target for FAP inhibitor (FAPI)-directed molecular imaging and endoradiotherapy (ERT). We aimed to assess the interobserver agreement rates for interpretation of Ga-68-FAPI-4 PET/CT and decision for ERT. Patients and Methods A random order of Ga-68-FAPI-4 PET/CTs from 49 oncology patients were independently interpreted by 4 blinded readers. Per scan, visual assessment was performed, including overall scan impression, number of organ/lymph node (LN) metastases, and number of affected organs/LN regions. Moreover, a maximum of 3 target lesions, defined as largest in size and/or most intense, per organ compartment were identified, which allowed for an additional quantitative interobserver assessment of LN and organ lesions. To investigate potential reference tissues, quantification also included unaffected liver parenchyma and blood pool. Readers also had to indicate whether FAPI-directed ERT should be considered (based on intensity of uptake and widespread disease). Interobserver agreement rates were evaluated using intraclass correlation coefficients (ICCs) and interpreted according to Cicchetti (with 0.4-0.59 indicating fair, and 0.6-0.74 good, agreement). Results On a visual basis, the agreement rate for an overall scan impression was fair (ICC, 0.42; 95% confidence interval [CI], 0.27-0.57). The concordance rate for number of affected LN areas was also fair (ICC, 0.59; 95% CI, 0.45-0.72), whereas the number of LN metastases, number of affected organs, and number of organ metastases achieved good agreement rates (ICC, >= 0.63). In a quantitative analysis, concordance rates for LN were good (ICC, 0.70; 0.48-0.88), but only fair for organ lesions (ICC, 0.43; 0.26-0.60). In regards to background tissues, ICCs were good for unaffected liver parenchyma (0.68; 0.54-0.79) and fair for blood pool (0.43; 0.29-0.58). When readers should decide on ERT, concordance rates were also fair (ICC, 0.59; 95% CI, 0.46-0.73). Conclusions For FAPI-directed molecular imaging and therapy, a fair to good interobserver agreement rate was achieved, supporting the adoption of this radiotracer for clinical routine and multicenter trials.
引用
收藏
页码:512 / 516
页数:5
相关论文
共 50 条
  • [1] Interobserver Agreement Rates on C-X-C Motif Chemokine Receptor 4-Directed Molecular Imaging and Therapy
    Hartrampf, Philipp E.
    Kosmala, Aleksander
    Serfling, Sebastian E.
    Bundschuh, Lena
    Higuchi, Takahiro
    Lapa, Constantin
    Rowe, Steven P.
    Matsusaka, Yohji
    Weich, Alexander
    Buck, Andreas K.
    Bundschuh, Ralph A.
    Werner, Rudolf A.
    CLINICAL NUCLEAR MEDICINE, 2023, 48 (06) : 483 - 488
  • [2] Associations between Normal Organs and Tumor Burden in Patients Imaged with Fibroblast Activation Protein Inhibitor-Directed Positron Emission Tomography
    Kosmala, Aleksander
    Serfling, Sebastian E.
    Dreher, Niklas
    Lindner, Thomas
    Schirbel, Andreas
    Lapa, Constantin
    Higuchi, Takahiro
    Buck, Andreas K.
    Weich, Alexander
    Werner, Rudolf A.
    CANCERS, 2022, 14 (11)
  • [3] Fibroblast Activation Protein α-Directed Imaging and Therapy of Solitary Fibrous Tumor
    Hamacher, Rainer
    Pabst, Kim M.
    Cheung, Phyllis F.
    Heilig, Christoph E.
    Hullein, Jennifer
    Liffers, Sven-Thorsten
    Borchert, Sabrina
    Costa, Pedro Fragoso
    Schaarschmidt, Benedikt M.
    Kessler, Lukas
    Miera, Monika A.
    Droste, Margret
    Akbulut, Merve
    Falkenhorst, Johanna
    Zarrad, Fadi
    Kostbade, Karina
    Mavroeidi, Ilektra A.
    Glimm, Hanno
    Umutlu, Lale
    Schuler, Martin
    Hubschmann, Daniel
    Bauer, Sebastian
    Frohling, Stefan
    Herrmann, Ken
    Siveke, Jens T.
    Schildhaus, Hans-Ulrich
    Fendler, Wolfgang P.
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65 (02) : 252 - 257
  • [4] Fibroblast Activation Protein Inhibitor Imaging in Nonmalignant Diseases: A New Perspective for Molecular Imaging
    Schmidkonz, Christian
    Kuwert, Torsten
    Atzinger, Armin
    Cordes, Michael
    Schett, Georg
    Ramming, Andreas
    Goetz, Theresa
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (12) : 1786 - 1792
  • [5] Fibroblast Activation Protein Inhibitor PET/CT A Promising Molecular Imaging Tool
    Sharma, Punit
    Singh, Shashank Shekhar
    Gayana, Shankaramurthy
    CLINICAL NUCLEAR MEDICINE, 2021, 46 (03) : e141 - e150
  • [6] The Latest Developments in Imaging of Fibroblast Activation Protein
    Altmann, Annette
    Haberkorn, Uwe
    Siveke, Jens
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (02) : 160 - 167
  • [7] Radiation Therapy Planning Using Fibroblast Activation Protein Inhibitor
    Koerber, Stefan A.
    PET CLINICS, 2023, 18 (03) : 369 - 380
  • [8] Fibroblast Activation Protein (FAP)-directed molecular imaging segregates between subtypes of poorly differentiated neuroendocrine neoplasms
    Weich, A.
    Wild, V
    Higuchi, T.
    Meining, A.
    Rowe, S.
    Pomper, M.
    Mielert, K.
    Rosenwald, A.
    Scheurlen, M.
    Buck, A.
    Serfling, S.
    Werner, R.
    JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 : 162 - 162
  • [9] Fibroblast Activation Protein Inhibitor-PET Imaging in Colorectal Cancer
    Strating, Esther
    van de Loo, Anne
    Elias, Sjoerd
    Lam, Marnix
    Kranenburg, Onno
    PET CLINICS, 2023, 18 (03) : 325 - 335
  • [10] Fibroblast Activation Protein Inhibitor Theranostics
    Raju, Shobhana
    Shukla, Jaya
    Kumar, Rakesh
    PET CLINICS, 2022, 17 (03) : 453 - 464